Clinical Experience of Personalized Phage Therapy Against Carbapenem-Resistant Acinetobacter baumannii Lung Infection in a Patient With Chronic Obstructive Pulmonary Disease

被引：80

作者：

Tan, Xin ^{[1
]}

Chen, Huaisheng ^{[2
]}

Zhang, Min ^{[3
,4
]}

Zhao, Ying ^{[5
]}

Jiang, Yichun ^{[2
]}

Liu, Xueyan ^{[2
]}

Huang, Wei ^{[3
,4
]}

Ma, Yingfei ^{[1
]}

机构：

[1] Chinese Acad Sci, Shenzhen Key Lab Synthet Genom, Guangdong Prov Key Lab Synthet Genom,Shenzhen Ins, CAS Key Lab Quantitat Engn Biol,Shenzhen Inst Syn, Shenzhen, Peoples R China

[2] South Univ Sci & Technol, Affiliated Hosp 1, Jinan Univ, Dept Crit Care Med,Shenzhen Peoples Hosp,Second C, Shenzhen, Peoples R China

[3] Shenzhen Peoples Hosp, Shenzhen Inst Resp Dis, Shenzhen, Peoples R China

[4] Southern Univ Sci & Technol, Affiliated Hosp 1, Jinan Univ,Shenzhen Peoples Hosp,Second Clin Med, Bacteriol & Antibacterial Resistance Surveillance, Shenzhen, Peoples R China

[5] Southern Univ Sci & Technol, Affiliated Hosp 1, Jinan Univ, Dept Geriatr,Shenzhen Peoples Hosp,Second Clin Co, Shenzhen, Peoples R China

来源：

FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY | 2021年 / 11卷

关键词：

carbapenem-resistant Acinetobacter baumannii; lung infection; personalized phage therapy; phage; endotoxin;

D O I：

10.3389/fcimb.2021.631585

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Overuse of antibiotics in clinical medicine has contributed to the global spread of multidrug-resistant bacterial pathogens, including Acinetobacter baumannii. We present a case of an 88-year-old Chinese man who developed hospital-acquired pneumonia caused by carbapenem-resistant A. baumannii (CRAB). A personalized lytic pathogen-specific single-phage preparation was nebulized to the patient continuously for 16 days in combination with tigecycline and polymyxin E. The treatment was well tolerated and resulted in clearance of the pathogen and clinical improvement of the patient's lung function.

引用

页数：7

共 50 条

[41] In vitro activity of rifabutin against 293 contemporary carbapenem-resistant Acinetobacter baumannii clinical isolates and characterization of rifabutin mode of action and resistance mechanisms
Trebosc, Vincent
Schellhorn, Birgit
Schill, Julian
Lucchini, Valentina
Buhler, Jacqueline
Bourotte, Marilyne
Butcher, Jonathan J.
Gitzinger, Marc
Lociuro, Sergio
Kemmer, Christian
Dale, Glenn E.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2020, 75 (12) : 3552 - 3562
[42] Piscidin is Highly Active against Carbapenem-Resistant Acinetobacter baumannii and NDM-1-Producing Klebsiella pneumonia in a Systemic Septicaemia Infection Mouse Model
Pan, Chieh-Yu
Chen, Jian-Chyi
Chen, Te-Li
Wu, Jen-Leih
Hui, Cho-Fat
Chen, Jyh-Yih
MARINE DRUGS, 2015, 13 (04) : 2287 - 2305
[43] Acute Exacerbation of Chronic Obstructive Pulmonary Disease Due to Carbapenem-Resistant Klebsiella pneumoniae-Induced Pneumonia: Clinical Features and Prognostic Factors
Ouyang, Pengwen
Zhou, Zhijie
Pan, Chanyuan
Tang, Peijuan
Long, Sheng
Liao, Xiangjian
Liu, Qiong
Xie, Liangyi
INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2024, 19 : 683 - 693
[44] Antimicrobial Susceptibility among Colistin, Sulbactam, and Fosfomycin and a Synergism Study of Colistin in Combination with Sulbactam or Fosfomycin against Clinical Isolates of Carbapenem-Resistant Acinetobacter baumannii
Leelasupasri, Sombat
Santimaleeworagun, Wichai
Jitwasinkul, Tossawan
JOURNAL OF PATHOGENS, 2018, 2018
[45] IN VITRO ACTIVITY OF COLISTIN OR SULBACTAM IN COMBINATION WITH FOSFOMYCIN OR IMIPENEM AGAINST CLINICAL ISOLATES OF CARBAPENEM-RESISTANT ACINETOBACTER BAUMANNII PRODUCING OXA-23 CARBAPENEMASES
Santimaleeworagun, Wichai
Wongpoowarak, Payom
Chayakul, Pantip
Pattharachayakul, Sutthiporn
Tansakul, Pimpimon
Garey, Kevin W.
SOUTHEAST ASIAN JOURNAL OF TROPICAL MEDICINE AND PUBLIC HEALTH, 2011, 42 (04) : 890 - 900
[46] National Survey of Thai Infectious Disease Physicians on Treatment of Carbapenem-Resistant Acinetobacter baumannii Ventilator-Associated Pneumonia: The Role of Infection Control Awareness
Buppajarntham, Aubonphan
Apisarnthanarak, Anucha
Khawcharoenporn, Thana
Rutjanawech, Sasinuch
Singh, Nalini
INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY, 2016, 37 (01): : 61 - 69
[47] Molecular epidemiology and patient outcome of carbapenem-resistant Enterobacterales, Pseudomonas aeruginosa and Acinetobacter baumannii in Japan: a multicenter study from MultiDrug-Resistant organisms clinical research network
Saito, Sho
Sakurai, Aki
Matsumura, Yasufumi
Uemura, Kohei
Hase, Ryota
Kato, Hideaki
Itoh, Naoya
Hashimoto, Takehiro
Matono, Takashi
Yu, Jiefu
Hayakawa, Kayoko
Suzuki, Masahiro
Izumi, Shoki
Suzuki, Tetsuya
Kurokawa, Mari
Shinohara, Koh
Mori, Keiichiro
Endo, Yasunobu
Mito, Haruki
Sano, Kayoko
Matsunaga, Tomo
Akazawa, Nana
Hiramatsu, Kazufumi
Asai, Yusuke
Tsuzuki, Shinya
van Duin, David
Ohmagari, Norio
Doi, Yohei
JAC-ANTIMICROBIAL RESISTANCE, 2025, 7 (02):
[48] Analysis of Acinetobacter baumannii resistance patterns in patients with chronic obstructive pulmonary disease (COPD) in terms of choice of effective empiric antibiotic therapy
Grochowalska, Aneta
Koziol-Montewka, Maria
Sobieszczanska, Anna
ANNALS OF AGRICULTURAL AND ENVIRONMENTAL MEDICINE, 2017, 24 (02) : 307 - 311
[49] In Vitro Activity of the Ultra-Broad-Spectrum Beta-Lactamase Inhibitor QPX7728 in Combination with Meropenem against Clinical Isolates of Carbapenem-Resistant Acinetobacter baumannii
Nelson, Kirk
Rubio-Aparicio, Debora
Tsivkovski, Ruslan
Sun, Dongxu
Totrov, Maxim
Dudley, Michael
Lomovskayaa, Olga
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2020, 64 (11)
[50] Adjunctive therapy of intravenous colistin to intravenous tigecycline for adult patients with non-bacteremic post-surgical intra-abdominal infection due to carbapenem-resistant Acinetobacter baumannii
Chusri, Sarunyou
Singkhamanan, Kamonnut
Wanitsuwan, Worrawit
Suphasynth, Yuthasak
Kositpantawong, Narongdet
Panthuwong, Siripen
Doi, Yohei
JOURNAL OF INFECTION AND CHEMOTHERAPY, 2019, 25 (09) : 681 - 686

← 1 2 3 4 5 →